摘要
在全球范围内,肺癌是造成癌症死亡的最主要原因。非小细胞肺癌（non-small cell lung cancer,NSCLC）约占肺癌的80%,由于缺乏早期诊断的有效手段,临床上首诊NSCLC患者仅25%~30%可选择根治性手术。对于不能手术切除的局部晚期及晚期NSCLC,单纯放射治疗或放化疗综合治疗是主要治疗手段,但总体疗效并不理想。近年来,靶向药物开创了NSCLC个体化治疗时代,越来越多的证据提示以表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs）为代表的靶向药物联合放疗或放化疗治疗NSCLC具有一定的前景。本文就EGFR-TKIs联合放疗治疗不可手术的局部晚期及晚期NSCLC的新进展做一综述。
Lung cancer is the main cause of cancer-related death worldwide. Non-small cell lung cancer （NSCLC） accounts for about 80% of lung cancer cases, but only 25%-30% of initially diagnosed patients have the option of radical surgery because of the lack of effective measures for early diagnosis. For locally advanced and advanced NSCLC, radiotherapy alone or comprehensive treatment with chemoradiotherapy is the main treatment method; however, the curative effect is unsatisfactory. Recently, increasing evidence sug- gests that targeted drugs, such as epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs）, combined with radiotherapy/ chemoradiotherapy represent a promising treatment modality for NSCLC. This review will discuss the research status of EGFR-TKIs and radiotherapy for locally advanced and advanced NSCLC.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2015年第23期1113-1117,共5页
Chinese Journal of Clinical Oncology
基金
supported by the National Natural Science Foundation of China(No.81272611
81301927)
Zhejiang Provincial Natural Science Foundation(No.LY13H160023)
the Medical and Scientific Research Projects of Hangzhou City(No.20150633B42)
